PROTEXI is a cancer vaccine platform that repurposes pre-existing antiviral immune memory from COVID-19 by linking tumor antigens with SARS-CoV-2 spike epitopes to activate both helper and cytotoxic T cells, aiming to redirect antiviral memory toward cancer.

In preclinical models of melanoma and breast cancer, PROTEXI slowed tumor growth, improved survival, and converted immune-evasive tumors into ones more recognizable by the immune system, with effects persisting in humanized mice.

Experts say this approach could shift the paradigm from building new immune responses to reusing existing antiviral memories, potentially extending to multiple cancer types, including immune-cold tumors.

The study was published in Nature Communications on July 27, 2026, by researchers from Celloram Inc., University Hospitals, and Case Western Reserve University, in collaboration with MedPacto and others.

The work was led by researchers from Celloram Inc., University Hospitals, and Case Western Reserve University, with publication detailing the findings in Nature Communications.

The press release notes ongoing collaboration with MedPacto and University Hospitals and signals plans for clinical translation in sarcoma and possibly other cancers.

Clinical translation is moving toward first-in-human trials in sarcoma to assess safety, feasibility, and immunologic activity, with potential expansion to other cancers if successful.

The MedPacto collaboration and translational efforts aim to bring PROTEXI from bench to bedside, seeking benefits for cancers with limited current options.

Investigators emphasize the translational potential and the prospect of advancing PROTEXI to human trials, highlighting the strategy of redirecting antiviral memory to eradicate cancer.

The study leadership from Celloram Inc., University Hospitals, and Case Western Reserve University outlined advancing PROTEXI toward sarcoma trials to evaluate safety, feasibility, and immunologic response.

Senior authors describe a path to first-in-human sarcoma trials, presenting PROTEXI as a potential paradigm shift in cancer vaccination.

Key collaborators include Celloram Inc., University Hospitals Cleveland Medical Center, and Case Western Reserve University, with support from the Case Comprehensive Cancer Center and NIH/NCI.